Compare CABA & CHMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CABA | CHMG |
|---|---|---|
| Founded | 2017 | 1833 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.6M | 339.8M |
| IPO Year | 2019 | 1995 |
| Metric | CABA | CHMG |
|---|---|---|
| Price | $3.01 | $71.45 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | $14.50 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 4.1M | 37.3K |
| Earning Date | 05-14-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | ★ 10.26 | N/A |
| EPS | N/A | ★ 1.91 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $37.32 |
| Revenue Next Year | N/A | $9.13 |
| P/E Ratio | ★ N/A | $37.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $48.61 |
| 52 Week High | $4.23 | $73.84 |
| Indicator | CABA | CHMG |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 58.60 |
| Support Level | $2.11 | $51.12 |
| Resistance Level | $3.48 | $73.84 |
| Average True Range (ATR) | 0.26 | 2.15 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 21.12 | 60.66 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Chemung Financial Corp is a bank holding firm. Through its subsidiaries, the company provides various financial services, including demand, savings, and time deposits, commercial, residential, and consumer loans, letters of credit, wealth management services, employee benefit plans, insurance products, mutual funds, and brokerage services, among others. The company's reportable segments are Core Banking, Wealth Management (WMG) services, and Holding company and CFS. Maximum revenue is generated from the Core Banking segment, which derives revenue by attracting deposits from the general public and using such funds to originate different types of loans, and to invest in securities. The Wealth Management (WMG) services segment provides trust and investment advisory services to clients.